Anika Therapeutics Inc. (ANIK) News
Filter ANIK News Items
ANIK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANIK News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ANIK News From Around the Web
Below are the latest news stories about ANIKA THERAPEUTICS INC that investors may wish to consider to help them evaluate ANIK as an investment opportunity.
We Think Anika Therapeutics (NASDAQ:ANIK) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Anika To Participate in 43rd Annual J.P. Morgan Healthcare ConferenceBEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on |
Sidoti Events, LLC's Virtual December Small-Cap ConferenceNEW YORK, NY / ACCESSWIRE / December 3, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ... |
Anika To Participate in December 2024 Investor ConferencesBEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences. 36th Annual Piper Sandler Healthcare Conference in New York, NY on December 3rd. Dr. Cheryl Blanchard, President and CEO of Anika and Steve Griffin, Executive Vice President and Chief Financial Officer, are scheduled to present at 10:30am ET. |
Anika Therapeutics Third Quarter 2024 Earnings: Misses ExpectationsAnika Therapeutics ( NASDAQ:ANIK ) Third Quarter 2024 Results Key Financial Results Revenue: US$38.8m (down 6.5% from... |
Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ...Anika Therapeutics Inc (ANIK) navigates revenue challenges with a focus on HA-based products and international growth. |
Arthrosurface Returns to it Roots Following Divestiture from Anika TherapeuticsExecutive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ: ANIK). Two former Arthrosurface leaders joined the Primo Medical Group executives in this strategic acquisition which ensures that Arthrosurface's position as a leader in orthopedic joint preservation solutions will resume with its portfolio of innovative products and expe |
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue EstimatesAnika (ANIK) delivered earnings and revenue surprises of -183.33% and 8.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Anika: Q3 Earnings SnapshotANIK) on Thursday reported a loss of $29.9 million in its third quarter. On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of $2.03. Losses, adjusted for asset impairment costs and stock option expense, were 25 cents per share. |
Anika Reports Third Quarter 2024 Financial ResultsUpdating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to focus on market leading OA Pain Management and high-growth Regenerative Solutions Company to categorize revenue into OEM Channel and Commercial Channel; Commercial Channel remains on track to achieve ~17% CAGR since 2021 with recent performance fueled by the IntegrityTM Implant System |